SHOSHONE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 496 cases of invasive cancer were diagnosed among Shoshone County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Shoshone County and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Shoshone County	State of Idaho			
All Sites/Types	496	47,333			
Female Breast	44	6,943			
Prostate	69	6,766			
Lung & Bronchus	90	4,959			
Colorectal	58	3,632			

Table 3 (Cancer Incidence 2017–2021, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Shoshone County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Shoshone County was 766.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.6) gives an estimate of the relative burden of disease in Shoshone County.

The age- and sex-adjusted incidence rate of invasive cancer in Shoshone County, all sites combined, was 572.1 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Shoshone County (496) than expected (454.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 166 Shoshone County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Shoshone County and the State of Idaho, 2018–2022

Mortality 2018–2022	Shoshone County	State of Idaho			
All Deaths	1,009	80,538			
Cancer Deaths	166	15,233			
% of All Deaths	16.5%	18.9%			
Lung & Bronchus	42	2,937			
Colorectal	21	1,332			
Pancreas	13	1,190			
Female Breast	9	1,111			
Prostate	15	997			

Table 4 (Cancer Mortality 2018–2022, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Shoshone County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Shoshone County, all sites combined, was 181.7 deaths per 100,000 persons per year during 2018–2022, compared with 164.8 for the remainder of the state. There were more cancer deaths in Shoshone County (166) than expected (150.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Lung and Bronchus Female 38 32,077 118.5 84.4 24.5 0.014 >> 2,426 4,447,756 54.5 Melanoma of the Skin Total 19 64,730 29.4 22.6 29.4 0.055 3,125 8,927,376 35.0 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9 Melanoma of the Skin Female 3 32,077 9.4 7.5 11.2 0.009 < 1,246 4,447,756 28.0 Myeloma Total 3 64,730 4.6 3.3 7.3 0.136 725 8,927,376 8.1 Myeloma Male - 32,653 - - 4.5 0.022 < 447 4,479,620 10.0 Myeloma Female 3 32,077 9.4 6.8 2.8 1.000 278 4,447,756 6.3 Non-Hodgkin Lymphoma Total 15 64,730<			Shoshone County						Remainder of Idaho			
All Siles Combined Male All Siles Combined Male Ma	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
All Siles Combined All Siles Combined All Siles Combined Female Bioldoff Folial Final All Siles Combined Female Folial Final Female Final All Siles Combined Female Final Fema	Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)			` '	
All Sites Combined Female 188 32.077 568.1 448.5 206.2 0.216 21.875 4.447.756 491.8 Bladder Female 17 64.75 28.5 28.5 0.285 0.225												
Bladder												
Bladder Female 3 32,077 9,4 6.7 4.5 0.692 4.44 4,447,756 10.0	=									,		
Brain - malsgrant												
Brain - malignant Male 3 32,633 9.2 7.5 3.4 1,000 379 4,479,620 8.5			-									
Brain and other CNS - non-malignant 1 32,077 3.1 2.5 2.5 0.592 274 4.447,756 6.2 Brain and other CNS - non-malignant 101 32,837 3.1 2.4 4.6 0.110 4.95 4.795 7.776 7.172 11.1 1	Brain - malignant Brain - malignant											
Brain and other CNS - non-malignant Female 9 32,077 28.1 21.8 96 1.000 4.79,620 11.1 Brain and other CNS - non-malignant Female 9 32,077 28.1 21.8 96 1.000 4.58 5.27,376 78.0 Breast Notal 9 4.79,620 13.9 10.8 4.77,76 23.3 Breast Notal 9 4.79,620 13.9 10.8 4.77,76 12.3 Breast State Notal 9 4.79,76 13.9 10.8 12.7 0.372 1.03,74 13.9 10.8 Breast In situ Total 9 64.730 13.9 10.8 12.7 0.372 1.03,74 13.9 10.8 Breast In situ Female 9 32,077 28.1 22.1 12.4 0.419 1.566 4.447,766 63.5 Breast In situ Female 9 32,077 28.1 22.1 12.4 0.419 1.566 4.447,766 63.5 Coliverdal Notal 48.8 48.8 48.8 48.8 48.8 48.8 48.8 Coliverdal Notal 49.8 48.8 48.8 48.8 48.8 48.8 Coliverdal Female 18 32,077 65.1 42.2 15.7 0.627 18.8 0.000 >> 1.837 4.47,756 44.7 Esophagus Male 5 32,633 15.3 11.0 4.3 0.880 424 4.47,56 0.56 Esophagus Male 5 32,633 15.3 11.0 4.3 0.880 424 4.47,96 0.56 Esophagus Male 5 32,633 15.3 11.0 4.3 0.880 424 4.47,96 0.56 Esophagus Male 7 32,633 7 7 7 7 7 7 7 7 7	Brain - malignant		•	32,077	3.1					4,447,756		
Branand other CNS - non-malignant Female 9 32,077 28.1 21.8 9.6 1.000 1.038 4.447,766 23.3 Breast Male 1 32,653 33.1 2.3 0.6 0.931 64 4.479,620 13.4 Breast Male 1 32,653 33.1 2.3 0.6 0.931 64 4.479,620 15.1 Breast Male 4 32,653 33.1 2.3 0.6 0.931 64 4.479,620 15.1 Breast mith Male 7 32,653 33.2 10.8 10.7 Breast mith Male 9 32,077 28.1 10.8 10.7 Breast mith Male 9 32,077 28.1 22.1 12.4 0.419 1.356 4.447,756 15.1 Breast mith Male 9 32,077 28.1 22.1 12.4 0.419 1.356 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Cervix Female 4 32,077 12.5 11.6 2.2 0.378 290 4.447,756 0.55 Colorectal Male 5 32,633 12.5 32.1 18.8 0.000 > 1.937 4.479,620 4.32 Colorectal Male 5 32,633 13.3 12.5 32.1 18.8 0.000 > 1.937 4.479,620 4.32 Esophagus Male 5 32,663 15.3 11.0 4.3 0.860 4.44 4.479,620 9.5 Esophagus Female - 32,077 0.8 0.916 7.8 4.447,766 1.8 Esophagus Female - 32,077 0.8 0.916 7.8 4.447,766 1.8 Esophagus Female - 32,077 0.8 0.916 7.8 4.447,766 1.8 Esophagus Female - 32,077 0.8 0.916 7.8 4.447,820 2.9 Esophagus Female - 32,077 0.8 0.916 7.7 1.3 0.7 Esophagus Female - 32,077 0.8 0.916 7.7 1.3 0.7 Esophagus Female - 32,077 0.8 0.916 7.7 1.3 0.7 Esophagus Female - 32,077 0.8 0.916 7.7 1.3 0.7 Esophagus Female - 32,077 0.8 0.916												
Breast Tofal 45 64,730 69.5 53.4 65.7 0.009 6,963 3,927,376 78.0 18.0			•									
Breast Female 44 32,077 137.2 106.4 64.1 0.010 < 6,899 4.447,756 155.1			-									
Breast - in situ			•									
Breast - in situ												
Breast Female			-		-	-						
Colorectal Male 40 32,653 122,5 92,1 18,8 0,000 >> 3,574 8,927,376 40,0 Colorectal Male 40 32,653 122,5 92,1 18,8 0,000 >> 1,937 4,479,756 36,8 Corpus Uteri Female 14 32,077 56,1 42,2 15,7 0,627 1,937 4,447,756 36,8 Corpus Uteri Female 14 32,077 56,1 42,2 15,7 0,627 1,937 4,447,756 36,8 Corpus Uteri Female 5 32,653 15,3 11,0 43, 0,800 424 4479,620 95,5 56,8 50,9 1,000 502 8,927,376 5,6 55,9 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 502 8,927,376 5,6 5,0 1,000 503 8,927,376 2,5 5,0 5,			9	32,077				0.419	-			
Colorectal Male 40 32,653 122,5 92.1 18.8 0.000 >> 19.97 4479,620 43.2	-		-									
Colorectal Female 18 32,077 56.1 42.2 15.7 0.627 16.37 4.447,756 36.8												
Corpus Uferi												
Sophagus	-	Female	14	32,077	43.6	33.5	12.6	0.766	1,340	4,447,756	30.1	
Esophagus												
Hodgkin Lymphoma Total			_									
Hodgiki Lymphoma	. 0					-						
Kidney and Renal Pelvis Male 10 32,653 30,6 22,9 12,7 18,6 0,477 1,936 8,927,376 21,7 Kidney and Renal Pelvis Female 5 32,077 15,6 11,8 6.0 0,879 636 4,447,756 14,3 Layrix Total 5 54,730 7,7 5,6 22,0 13,7 215 8,927,376 24,447,756 14,3 Layrix Male 4 32,653 12,3 8,8 1,7 0,173 163 4,479,620 3,6 Layrix Female 1 32,077 3,1 2,3 0,5 0,792 52 4,447,756 12,2 Leukemia Total 16 64,730 24,7 18,6 16,4 1,000 1,711 8,927,376 12,2 Leukemia Male 12 32,653 36,8 27,8 9,9 0,579 1,024 4,479,620 22,9 Leukemia Female 1 32,077 12,5 9,4 6,6 0,435 6,87 4,447,756 15,4 Liver and Bile Duct Male 12 32,653 36,8 26,4 5,9 0,035 562 4,447,756 15,4 Liver and Bile Duct Male 12 32,653 36,8 26,4 5,9 0,035 562 4,479,620 13,0 Liver and Bile Duct Male 12 32,653 36,8 26,4 5,9 0,035 562 4,479,620 13,0 Liver and Bile Duct Male 12 32,653 36,8 26,4 5,9 0,035 562 4,479,620 13,0 Liver and Bile Duct Male 12 32,653 36,8 26,4 5,9 0,035 562 4,479,620 13,0 Liver and Bile Duct Male 52 32,653 159,3 112,2 25,3 0,000 2,443 4,477,65 5,5 Lung and Bronchus Male 52 32,653 159,3 112,2 25,3 0,000 2,443 4,477,65 5,5 Lung and Bronchus Female 3 32,077 18,5 84,4 5,0014 2,424 4,447,765 54,5 Melanoma of the Skin Male 52 32,653 159,3 112,2 25,3 0,000 2,443 4,479,620					-	-						
Kidney and Renal Pelvis Male 10 32,653 30,6 22.9 12.7 0.561 1,300 4,479,620 29.0 4,477,66 13.1 1,300 4,479,620 29.0 1,300 4,479,620 29.0 1,300 4,479,620 29.0 1,300 4,479,620 29.0 1,300 1,300 1,300 1,300 1,479,620 29.0 1,30					-	-						
Kidney and Renal Pelvis Female 5 32,077 15.6 11.8 6.0 0.879 636 4,447,756 14.3 Larynx												
Larynx												
Larymx Male												
Leukemia Total 16 64,730 24,7 18,6 16,4 1,000 1,711 8,927,376 19.2										4,479,620		
Leukemia Male 12 32,653 36.8 27.8 9.9 0.579 1,024 4,479,620 22.9			•									
Leukemia Female 4 32,077 12.5 9.4 6.6 0.435 687 4,447,756 15.4 Liver and Bile Duct Total 16 64,730 24.7 18.0 8.2 0.021 >> 827 8,927,376 9.3 Liver and Bile Duct Female 4 32,077 12.5 9.2 2.4 0.443 245 4,447,766 5.5 Lung and Bronchus Total 90 64,730 139.0 98.5 49.8 0.000 >> 2,443 4,479,620 54.5 Lung and Bronchus Male 52 32,2653 159.3 112.2 25.3 0.000 >> 2,443 4,479,620 54.5 Lung and Bronchus Female 38 32,077 118.5 84.4 24.5 0.014 >> 2,426 4,447,756 54.5 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9												
Liver and Bile Duct Male Liver and Bile Duct 4 32,077 12.5 9.2 2.4 0.036 >> 582 4.479,620 13.0 Liver and Bile Duct Female 4 32,077 12.5 9.2 2.4 0.443 245 4.447,756 5.5 Lung and Bronchus Male 52 32,653 159.3 112.2 25.3 0.000 >> 2,443 4,477,66 5.5 Lung and Bronchus Female 38 32,077 118.5 8.4.4 24.5 0.000 >> 2,443 4,479,620 54.5 Lung and Bronchus Female 38 32,077 118.5 8.4.4 24.5 0.000 >> 2,443 4,479,620 54.5 Melanoma of the Skin Total 19 64,730 29.4 22.6 29.4 0.055 3,125 8.927,376 35.0 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 18.79 4,477,56 28.0 Myeloma Male 32												
Liver and Bile Duct Female 4 32,077 12.5 9.2 2.4 0.443 245 4,447,756 5.5 Lung and Bronchus Intal 90 64,730 139,0 98.5 49.8 0.000 >> 4,869 8,927,376 54.5 Lung and Bronchus Female 38 32,077 118.5 84.4 24.5 0.014 >> 2,426 4,447,756 54.5 Melanoma of the Skin Total 19 64,730 29.4 22.6 29.4 0.055 3,125 8,927,376 54.5 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9 Melanoma of the Skin Female 3 32,077 9.4 6.8 3.3 7.3 0.136 725 8,927,376 8.1 Myeloma Male - 32,653 - - 4.5 0.022 <										8,927,376		
Lung and Bronchus										4,479,620		
Lung and Bronchus Male 52 32,653 159,3 112,2 25,3 0.000 >> 2,443 4,479,620 54,5 Lung and Bronchus Female 38 32,077 118,5 84.4 24.5 0.014 >> 2,426 4,447,756 54.5 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9 Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9 Melanoma of the Skin Female 3 32,077 9.4 7.5 11.2 0.009 4.79,620 41.9 Myeloma Male - 32,653 - - 4.5 0.022 47 4,477,620 28.0 Myeloma Male - 32,653 - - 4.5 0.022 47 4,479,620 10.0 Myeloma Female 3 32,077 9.4			-									
Melanoma of the Skin Male 19 64,730 29,4 22,6 29,4 0.055 3,125 8,927,376 35,0 Melanoma of the Skin Male 16 32,653 49,0 36,9 18,2 0.713 1,879 4,479,620 41,2 Melanoma of the Skin Female 3 32,077 9,4 7,5 11,2 0.009 1,246 4,447,756 28,0 Myeloma Male - 32,653 4,5 0.022 447 4,479,620 10,0 Myeloma Male - 32,653 4,5 0.022 447 4,479,620 10,0 Myeloma Total 15 64,730 23,2 17,4 19,1 0.415 1,977 8,927,376 22,1 Non-Hodgkin Lymphoma Total 15 64,730 23,2 17,4 19,1 0.415 1,977 8,927,376 22,1 Non-Hodgkin Lymphoma Female 8 32,077 24,9 18,6 8,1 1,000 8,38 4,447,756 18,8 Oral Cavity and Pharynx Total 20 64,730 30,9 22,9 12,7 0.070 1,295 8,927,376 14,5 Oral Cavity and Pharynx Male 17 32,653 52,1 38,1 9,2 0.027 9,23 4,447,56 18,8 Oral Cavity and Pharynx Female 3 32,077 12,5 9,7 5,1 0.848 549 4,447,56 12,3 Pancreas Total 17 64,730 26,3 18,9 14,8 0.633 1,471 8,927,376 16,5 Pancreas Female 8 32,653 24,5 17,7 8,3 1,000 8,18 4,447,56 18,3 Pancreas Female 9 32,653 21,3 148,5 69,5 1,000 6,697 4,479,620 149,5 Stomach Male 4 32,653 11,3 148,5 69,5 1,000 6,697 4,479,620 149,5 Stomach Female - 32,077 - - 1,6 0.402 167 4,447,756 3,8 Total 3 64,730 4,6 3,4 4,6 0.646 4,711 8,927,376 6,8 Stomach Female - 32,077 - - 1,6 0.402 167 4,447,756 3,8 Total 3 64,730 4,6 3,4 4,6 0.646 4,711 8,927,376 6,8 Stomach Female - 32,077 - - 1,6 0.402 167 4,447,756 3,8 Total 3 64,730 4,6 3,4 4,6 0.646 4,711 8,927,376 6,8 Stomach Female - 32,077 - - 1,6 0.402 167 4,447,756 3,8 Total 8 64,730 12,3 13,5 18 0.213 270 4,447,756 3,8 Total	Lung and Bronchus											
Melanoma of the Skin Male 16 32,653 49.0 36.9 18.2 0.713 1,879 4,479,620 41.9 Melanoma of the Skin Female 3 32,077 9.4 7.5 11.2 0.009 <	Lung and Bronchus											
Melanoma of the Skin Female 3 32,077 9.4 7.5 11.2 0.009 < 1,246 4,447,756 28.0 Myeloma Total 3 64,730 4.6 3.3 7.3 0.136 725 8,927,376 8.1 Myeloma Female 3 32,077 9.4 6.8 2.8 1.000 278 4,447,756 6.3 Non-Hodgkin Lymphoma Total 15 64,730 23.2 17.4 19.1 0.415 1,977 8,927,376 22.1 Non-Hodgkin Lymphoma Male 7 32,653 21.4 16.1 11.1 0.278 4,447,756 6.3 Non-Hodgkin Lymphoma Female 8 32,077 24.9 18.6 8.1 1.000 838 4,477,56 18.8 Oral Cavity and Pharynx Total 20 64,730 30.9 22.9 12.7 0.070 1,295 8,927,376 14.5 Oral Cavity and Pharynx Male 17 32,653												
Myeloma Total 3 64,730 4.6 3.3 7.3 0.136 725 8,927,376 8.1 Myeloma Male - 32,653 - - 4.5 0.022 447 4,479,620 10.0 Myeloma Female 3 32,077 9.4 6.8 2.8 1.000 278 4,447,756 6.3 Non-Hodgkin Lymphoma Total 15 64,730 23.2 17.4 19.1 0.415 1,977 8,927,376 22.1 Non-Hodgkin Lymphoma Male 7 32,653 21.4 16.1 11.1 0.278 1,139 4,479,620 25.4 Non-Hodgkin Lymphoma Female 8 32,077 24.9 18.6 8.1 1.000 838 4,447,756 18.8 Oral Cavity and Pharynx Total 20 64,730 30.9 22.9 12.7 0.070 1,295 8,927,376 14.5 Oral Cavity and Pharynx Male 17 32,653 <td></td>												
Myeloma Female 3 32,077 9.4 6.8 2.8 1.000 278 4,447,756 6.3 Non-Hodgkin Lymphoma Total 15 64,730 23.2 17.4 19.1 0.415 1,977 8,927,376 22.1 Non-Hodgkin Lymphoma Male 7 32,653 21.4 16.1 11.1 0.278 1,139 4,479,620 25.4 Non-Hodgkin Lymphoma Female 8 32,077 24.9 18.6 8.1 1.000 838 4,447,756 18.8 Oral Cavity and Pharynx Total 20 64,730 30.9 22.9 12.7 0.070 1,295 8,927,376 14.5 Oral Cavity and Pharynx Male 17 32,653 52.1 38.1 9.2 0.027 923 4,474,756 8.4 Oral Cavity and Pharynx Female 3 32,077 9.4 7.0 3.6 1.000 372 4,447,756 20.6 Oral Cavity and Pharynx Female	Myeloma			64,730			7.3			8,927,376		
Nón-Hodgkin Lymphoma Total 15 64,730 23.2 17.4 19.1 0.415 1,977 8,927,376 22.1 Non-Hodgkin Lymphoma Male 7 32,653 21.4 16.1 11.1 0.278 1,139 4,479,620 25.4 Non-Hodgkin Lymphoma Female 8 32,077 24.9 18.6 8.1 1.000 838 4,447,756 18.8 Oral Cavity and Pharynx Total 20 64,730 30.9 22.9 12.7 0.070 1,295 8,927,376 14.5 Oral Cavity and Pharynx Male 17 32,653 52.1 38.1 9.2 0.027 923 4,479,620 20.6 Oral Cavity and Pharynx Female 3 32,077 9.4 7.0 3.6 1.000 372 4,447,756 8.4 Ovary Female 4 32,077 12.5 9.7 5.1 0.848 549 4,447,756 12.3 Pancreas Male 8 <td>Myeloma</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4.5</td> <td></td> <td></td> <td>4,479,620</td> <td></td>	Myeloma						4.5			4,479,620		
Non-Hodgkin Lymphoma Male 7 32,653 21.4 16.1 11.1 0.278 1,139 4,479,620 25.4												
Non-Hodgkin Lymphoma Female 8 32,077 24.9 18.6 8.1 1.000 838 4,447,756 18.8 Oral Cavity and Pharynx Total 20 64,730 30.9 22.9 12.7 0.070 1,295 8,927,376 14.5 Oral Cavity and Pharynx Male 17 32,653 52.1 38.1 9.2 0.027 >> 923 4,479,620 20.6 Oral Cavity and Pharynx Female 3 32,077 9.4 7.0 3.6 1.000 372 4,447,756 8.4 Ovary Female 4 32,077 9.4 7.0 3.6 1.000 372 4,447,756 12.3 Pancreas Female 4 32,077 12.5 9.7 5.1 0.848 549 4,447,756 12.3 Pancreas Male 8 32,653 24.5 17.7 8.3 1.000 818 4,479,620 18.3 Pancreas Female 9 32,077												
Oral Cavity and Pharynx Male 17 32,653 52.1 38.1 9.2 0.027 >> 923 4,479,620 20.6 Oral Cavity and Pharynx Female 3 32,077 9.4 7.0 3.6 1.000 372 4,447,756 8.4 Ovary Female 4 32,077 12.5 9.7 5.1 0.848 549 4,447,756 12.3 Pancreas Total 17 64,730 26.3 18.9 14.8 0.633 1,471 8,927,376 16.5 Pancreas Male 8 32,653 24.5 17.7 8.3 1.000 818 4,479,620 18.3 Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4,447,756 14.7 Prostate Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 32,653 9.2	Non-Hodgkin Lymphoma	Female	8	32,077	24.9	18.6	8.1	1.000	838		18.8	
Oral Cavity and Pharynx Female 3 32,077 9.4 7.0 3.6 1.000 372 4,447,756 8.4 Ovary Female 4 32,077 12.5 9.7 5.1 0.848 549 4,447,756 12.3 Pancreas Total 17 64,730 26.3 18.9 14.8 0.633 1,471 8,927,376 16.5 Pancreas Male 8 32,653 24.5 17.7 8.3 1,000 818 4,479,620 18.3 Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4,447,662 18.3 Pancreas Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 64,730 4.6 3.4 4.6 0.646 471 8,927,376 5.3 Stomach Female - 32,077 - -	Oral Cavity and Pharynx				30.9				1,295	8,927,376		
Ovary Female 4 32,077 12.5 9.7 5.1 0.848 549 4,447,756 12.3 Pancreas Total 17 64,730 26.3 18.9 14.8 0.633 1,471 8,927,376 16.5 Pancreas Male 8 32,653 24.5 17.7 8.3 1,000 818 4,479,620 18.3 Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4,447,756 14.7 Prostate Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 64,730 4.6 3.4 4.6 0.646 471 8,927,376 5.3 Stomach Male 3 32,653 9.2 6.7 3.0 1.000 304 4,479,620 6.8 Stomach Female - 32,077 - - 1.6										4,479,620		
Pancreas Total 17 64,730 26.3 18.9 14.8 0.633 1,471 8,927,376 16.5 Pancreas Male 8 32,653 24.5 17.7 8.3 1.000 818 4,479,620 18.3 Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4,447,756 14.7 Prostate Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 32,653 9.2 6.7 3.0 1.000 304 4,479,620 6.8 Stomach Female - 32,077 - - 1.6 0.402 167 4,447,756 3.8 Stomach Female - 32,077 - - 1.6 <td></td>												
Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4,447,756 14.7 Prostate Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 64,730 4.6 3.4 4.6 0.646 471 8,927,376 5.3 Stomach Male 3 32,653 9.2 6.7 3.0 1.000 304 4,479,620 6.8 Stomach Female - 32,077 - - 1.6 0.402 167 4,447,756 3.8 Testis Male 4 32,653 12.3 13.5 1.8 0.213 270 4,479,620 6.0 Thyroid Total 8 64,730 12.4 11.1 9.5 0.791 1,177 8,927,376 13.2 Thyroid Male 6 32,653 18.4 15.3 3.2 <				64,730	26.3		14.8	0.633		8,927,376		
Prostate Male 69 32,653 211.3 148.5 69.5 1.000 6,697 4,479,620 149.5 Stomach Total 3 64,730 4.6 3.4 4.6 0.646 471 8,927,376 5.3 Stomach Male 3 32,653 9.2 6.7 3.0 1.000 304 4,479,620 6.8 Stomach Female - 32,077 - - 1.6 0.402 167 4,447,756 3.8 Testis Male 4 32,653 12.3 13.5 1.8 0.213 270 4,479,620 6.0 Thyroid Total 8 64,730 12.4 11.1 9.5 0.791 1,177 8,927,376 13.2 Thyroid Male 6 32,653 18.4 15.3 3.2 0.211 366 4,479,620 8.2												
Stomach Total 3 64,730 4.6 3.4 4.6 0.646 471 8,927,376 5.3 Stomach Male 3 32,653 9.2 6.7 3.0 1.000 304 4,479,620 6.8 Stomach Female - 32,077 - - 1.6 0.402 167 4,447,756 3.8 Testis Male 4 32,653 12.3 13.5 1.8 0.213 270 4,479,620 6.0 Thyroid Total 8 64,730 12.4 11.1 9.5 0.791 1,177 8,927,376 13.2 Thyroid Male 6 32,653 18.4 15.3 3.2 0.211 366 4,479,620 8.2				- , -								
Stomach Male Stomach 3 32,653 32,077 9.2												
Stomach Female - 32,077 - - 1.6 0.402 167 4,447,756 3.8 Testis Male 4 32,653 12.3 13.5 1.8 0.213 270 4,479,620 6.0 Thyroid Total 8 64,730 12.4 11.1 9.5 0.791 1,177 8,927,376 13.2 Thyroid Male 6 32,653 18.4 15.3 3.2 0.211 366 4,479,620 8.2	Stomach	Male		32,653			3.0	1.000		4,479,620	6.8	
Thyroid Total 8 64,730 12.4 11.1 9.5 0.791 1,177 8,927,376 13.2 Thyroid Male 6 32,653 18.4 15.3 3.2 0.211 366 4,479,620 8.2			-		-	-				4,447,756		
Thyroid Male 6 32,653 18.4 15.3 3.2 0.211 366 4,479,620 8.2												
	,											
program promator 21 02,077 0.21 0.31 0.21 0.107 1 011 4,447.730 1 10.2	,											
	Pediatric Age 0 to 19		1									
Pediatric Age 0 to 19 Male 1 7,417 13.5 13.3 1.3 1.000 213 1,266,904 16.8			1									
Pediatric Age 0 to 19 Female - 6,983 - - 1.2 0.595 211 1,218,020 17.3		Female	-		-	-						

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

^{2.} Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

[&]quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

TABLE 4: CANCER MORTALITY 2018–2022 COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Shoshone County						Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	1,009	66,231	1,523.5	1,125.7	779.5	0.000 >>	79,526	9,145,163	869.6	
All Causes of Death	Male	561	33,464	1,676.4	1,305.9	394.8	0.000 >>	42,225	4,594,233	919.1	
All Causes of Death	Female	448	32,767	1,367.2	953.8	385.0	0.002 >>	37,301	4,550,930	819.6	
All Malignant Cancers	Total	166	66,231	250.6	181.7	150.5	0.224	15,067	9,145,163	164.8	
All Malignant Cancers	Male	97 69	33,464	289.9	214.1 151.2	80.3 69.5	0.076 1.000	8,138 6,929	4,594,233 4,550,930	177.1 152.3	
All Malignant Cancers Bladder	Female Total	3	32,767 66,231	210.6 4.5	3.2	4.9	0.551	482	9,145,163	5.3	
Bladder	Male	3	33,464	9.0	6.8	3.6	1.000	372	4,594,233	8.1	
Bladder	Female	-	32,767	-	-	1.2	0.627	110	4,550,930	2.4	
Brain and Other Nervous System	Total	2	66,231	3.0	2.3	4.9	0.274	516	9,145,163	5.6	
Brain and Other Nervous System	Male	1	33,464	3.0	2.3	2.7	0.484	288	4,594,233	6.3	
Brain and Other Nervous System	Female	1	32,767	3.1	2.3	2.1	0.735	228	4,550,930	5.0	
Breast	Total	10	66,231	15.1	11.2	10.9	0.952	1,114	9,145,163	12.2	
Breast	Male	1	33,464	3.0	2.3	0.1	0.218	12	4,594,233	0.3	
Breast Cervix	Female Female	9	32,767 32,767	27.5	20.0	10.9 0.7	0.707 0.950	1,102 88	4,550,930 4,550,930	24.2 1.9	
Colorectal	Total	- 21	66,231	31.7	23.4	12.8	0.950	1,311	9,145,163	14.3	
Colorectal	Male	13	33,464	38.8	29.4	6.9	0.043	719	4,594,233	15.7	
Colorectal	Female	8	32,767	24.4	17.5	5.9	0.498	592	4,550,930	13.0	
Corpus Uteri	Female	1	32,767	3.1	2.2	1.7	1.000	168	4,550,930	3.7	
Esophagus	Total	7	66,231	10.6	7.6	4.6	0.353	454	9,145,163	5.0	
Esophagus	Male	7	33,464	20.9	15.1	3.9	0.196	384	4,594,233	8.4	
Esophagus	Female	-	32,767	-	-	0.7	0.986	70	4,550,930	1.5	
Hodgkin Lymphoma	Total	-	66,231	-	-	0.2	1.000	25	9,145,163	0.3	
Hodgkin Lymphoma	Male Female	-	33,464 32,767	-	-	0.1 0.1	1.000 1.000	14 11	4,594,233 4,550,930	0.3 0.2	
Hodgkin Lymphoma Kidney	Total	- 6	66,231	9.1	- 6.5	3.8	0.381	380	9,145,163	4.2	
Kidney	Male	3	33,464	9.0	6.6	2.4	0.866	243	4,594,233	5.3	
Kidney	Female	3	32,767	9.2	6.4	1.4	0.343	137	4,550,930	3.0	
Larynx	Total	-	66,231	-	-	0.8	0.924	76	9,145,163	0.8	
Larynx	Male	-	33,464	-	-	0.7	1.000	65	4,594,233	1.4	
Larynx	Female	-	32,767	-	-	0.1	1.000	11	4,550,930	0.2	
Leukemia	Total	4	66,231	6.0	4.4	6.6	0.428	661	9,145,163	7.2	
Leukemia	Male Female	4	33,464 32,767	12.0	8.9	3.8 2.7	1.000 0.134	393 268	4,594,233 4,550,930	8.6 5.9	
Leukemia Liver and Bile Duct	Total	- 6	66,231	9.1	6.6	6.3	1.000	629	9,145,163	6.9	
Liver and Bile Duct	Male	4	33,464	12.0	8.6	4.2	1.000	419	4,594,233	9.1	
Liver and Bile Duct	Female	2	32,767	6.1	4.4	2.1	1.000	210	4,550,930	4.6	
Lung and Bronchus	Total	42	66,231	63.4	45.1	29.5	0.034 >>	2,895	9,145,163	31.7	
Lung and Bronchus	Male	22	33,464	65.7	47.3	15.4	0.132	1,519	4,594,233	33.1	
Lung and Bronchus	Female	20	32,767	61.0	43.1	14.0	0.156	1,376	4,550,930	30.2	
Melanoma of the Skin	Total	5	66,231	7.5	5.6	2.9	0.335	296	9,145,163	3.2	
Melanoma of the Skin	Male	2	33,464	6.0	4.5	1.9	1.000	198	4,594,233	4.3	
Melanoma of the Skin Myeloma	Female Total	3 2	32,767 66,231	9.2 3.0	6.8 2.1	1.0 3.3	0.144 0.719	98 323	4,550,930 9,145,163	2.2 3.5	
Myeloma Mveloma	Male		33,464	3.0	2.1	3.3 1.9	0.719	323 188	9,145,163 4,594,233	3.5 4.1	
Myeloma	Female	2	32,767	6.1	4.3	1.4	0.809	135	4,550,930	3.0	
Non-Hodgkin Lymphoma	Total	4	66,231	6.0	4.3	5.7	0.656	564	9,145,163	6.2	
Non-Hodgkin Lymphoma	Male	1	33,464	3.0	2.2	3.1	0.383	309	4,594,233	6.7	
Non-Hodgkin Lymphoma	Female	3	32,767	9.2	6.3	2.7	0.991	255	4,550,930	5.6	
Oral Cavity and Pharynx	Total	4	66,231	6.0	4.4	2.7	0.571	271	9,145,163	3.0	
	Male	4	33,464	12.0	8.7	1.9	0.244	188	4,594,233	4.1	
Oral Cavity and Pharynx	Female	- 2	32,767	- 64	-	0.8	0.876	83	4,550,930	1.8	
Ovary Pancreas	Female Total	2 13	32,767 66,231	6.1 19.6	4.4 14.1	3.6 11.8	0.613 0.812	359 1,177	4,550,930 9,145,163	7.9 12.9	
Pancreas Pancreas	Male	6	33,464	17.9	14.1 12.9	6.5	1.000	644	9,145,163 4,594,233	14.0	
Pancreas	Female	7	32,767	21.4	15.3	5.4	0.581	533	4,550,930	11.7	
Prostate	Male	15	33,464	44.8	33.6	9.5	0.122	982	4,594,233	21.4	
Stomach	Total	1	66,231	1.5	1.1	1.9	0.890	193	9,145,163	2.1	
Stomach	Male	1	33,464	3.0	2.2	1.1	1.000	118	4,594,233	2.6	
Stomach	Female	-	32,767	-	-	0.7	0.989	75	4,550,930	1.6	
Natas.	1 Dates or		e number of cases	400 000							

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

^{2.} Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

	State of								Shoshone
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age < 65 (2021–2022)	90.0%	89.3%	87.8%	86.4%	92.6%	87.2%	89.1%	92.6%	95.9%
Not See Doctor Due to Cost in Past Year (2020–2022)	10.4%	9.5%	11.0%	11.0%	10.2%	10.2%	10.4%	11.3%	9.8%
Cancer Screening									
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years)	62.9%	61.0%	70.0%	60.3%	66.1%	58.9%	61.0%	62.5%	55.9%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.1%	73.7%	73.6%	70.9%	72.9%	69.4%	69.3%	65.5%	
Colorectal Cancer Screening, Age 45–75 (2022)	63.3%	61.0%	62.5%	60.8%	67.2%	65.0%	60.4%	60.2%	
Tobacco Use									
Current Tobacco User (2020–2022)	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.0%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2020–2022)	30.0%	30.0%	30.1%	26.5%	33.7%	27.5%	26.7%	30.2%	33.2%
Any Physical Activity Besides Job Past 30 Days (2018–2022)	79.1%	79.0%	78.0%	75.4%	82.7%	75.2%	76.7%	81.0%	68.7%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	22.0%	22.8%	19.2%	20.0%	25.2%	19.5%	20.4%	20.3%	19.7%
Home Ever Tested for Radon (2016, 2018, 2020)	22.9%	30.8%	18.3%	16.9%	25.2%	20.1%	23.0%	21.0%	29.3%

Access to Care

Have Health Insurance – 2021–2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year – 2020–2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

Pap Test - 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

<u>Colorectal Cancer Screening</u> – 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Cancer Screening and Risk Factors

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.



